Research progress on the application of fibroblast activation protein inhibitor PET/CT imaging in the diagnosis and treatment of bone and joint diseases
10.3760/cma.j.cn321828-20240129-00044
- VernacularTitle:成纤维细胞激活蛋白抑制剂PET/CT显像在骨与关节疾病诊治中的应用研究进展
- Author:
Xuezhi LIN
1
;
Guojian ZHANG
Author Information
1. 内蒙古医科大学第一临床医学院，呼和浩特 010050
- Publication Type:Journal Article
- Keywords:
Bone diseases;
Joint diseases;
Fibroblasts;
Antagonists and inhibitors;
Positron-emission tomography;
Tomography, X-ray computed;
Trends
- From:
Chinese Journal of Nuclear Medicine and Molecular Imaging
2025;45(2):120-124
- CountryChina
- Language:Chinese
-
Abstract:
Fibroblast activation protein (FAP) is overexpressed not only in cancer-associated fibroblasts, but also in bone and joint diseases. With the continuous expansion of the application range of radionuclide labeled FAP inhibitor (FAPI) PET/CT imaging, it has gradually shown a good potential in the clinical diagnosis and efficacy evaluation of bone and joint diseases. This paper reviews the animal and clinical studies of radionuclide-labeled FAPI PET/CT imaging in the diagnosis and treatment of bone and joint diseases like tumors, inflammation, Erdheim-Chester disease (ECD) and so on, aiming to further explore the characteristics of FAPI and expand the scope of clinical application.
